Strengths and limitations of industry vs. academic randomized controlled trials

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 906-909

  Laterre, P F ^a   Francois B ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Academic research; Clinical research; Controlled trials; Data monitoring; Industry; Study design

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS; DRUG INDUSTRY; FUNDING; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; INDUSTRY; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; HUMANS; INDUSTRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942196840     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.07.004     Document Type: Review

References (17)

1. Elia N., Wager E., Tramèr M.R. Fate of articles that warranted retraction due to ethical concerns: a descriptive cross-sectional study. PLoS One 2014, 9(1):e85846.
2. Prasad P., Sun J., Danner R.L., Nathanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709.
3. Blot S., Koulenti D., Akova M., Bassetti M., De Waele J.J., Dimopoulos G., et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 2014, 18(3):R99.
4. Doshi P. Speeding new antibiotics to market: a fake fix?. BMJ 2015, 350:h1453.
5. MacMahon S., Perkovic V., Patel A. Industry-sponsored clinical trials in emerging markets: Time to review the terms of engagement. JAMA 2013, 310(9):907-908.
6. Macias W.L., Vallet B., Bernard G.R., Vincent J.L., Laterre P.F., Nelson D.R., et al. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med 2004, 32(12):2385-2391.
7. Gehring M., Taylor R.S., Mellody M., Casteels B., Piazzi A., Gensini G., et al. Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study). BMJ Open 2013, 3(11):e002957.
8. Flacco M., Manzoli L., Boccia S., Capasso L., Aleksovska K., Rosso A., et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 2015, 68(7):811-820.
9. Lundh A., Sismondo S., Lexchin J., Busuioc O.A., Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012, 12:MR000033.
10. Chan J.K., Ueda S.M., Sugiyama V.E., Stave C.D., Shin J.Y., Monk B.J., et al. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?. J Clin Oncol 2008, 26(9):1511-1518.
11. Djulbegovic B., Kumar A., Miladinovic B., Reljic T., Galeb S., Mhaskar A., et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One 2013, 8(3):e58711.
12. Naci H., Dias S., Ades A.E. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014, 349:g5741.
13. Krauth D., Anglemyer A., Philipps R., Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol 2014 Jan, 12(1):e1001770.
14. van Lent M., Rongen G.A., Out H.J. Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review. BMC Med Ethics 2014, 15:83.
15. Patwardhan S., Gogtay N., Thatte U., Pramesh C.S. Quality and completeness of data documentation in an investigator-initiated trial versus an industry-sponsored trial. Indian J Med Ethics 2014, 11:19-24.
16. Hughes S., Cohen D., Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 2014, 4(7):e005535.
17. Strom B.L., Buyse M., Hughes J., Knoppers B.M. Data sharing, year 1-access to data from industry-sponsored clinical trials. N Engl J Med 2014, 371(22):2052-2054.